Role of FDG PET/CT and chest CT in the follow-up of lung lesions treated with radiofrequency ablation

Radiology

Volumn 258, Issue 1, 2011, Pages 270-276

  Deandreis, Désirée ^a   Leboulleux, Sophie ^a   Dromain, Clarisse ^a   Auperin, Anne ^a   Coulot, Jérémy ^a   Lumbroso, Jean ^a   Deschamps, Frédéric ^a   Rao, Pramod ^a   Schlumberger, Martin ^a   De Baère, Thierry ^a  

^a INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

[No Author keywords available]

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

ADULT; ARTICLE; CANCER PATIENT; CLINICAL ARTICLE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; COMPUTER ASSISTED TOMOGRAPHY; EVALUATION; FALSE NEGATIVE RESULT; FALSE POSITIVE RESULT; FEMALE; FOLLOW UP; HUMAN; INTERMETHOD COMPARISON; LUNG CANCER; LUNG METASTASIS; MALE; MEDIASTINUM LYMPH NODE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PUNCTURE; RADIOFREQUENCY ABLATION; TREATMENT PLANNING;

CATHETER ABLATION; FEMALE; FLUORODEOXYGLUCOSE F18; FOLLOW-UP STUDIES; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; RADIOGRAPHY, THORACIC; RADIOPHARMACEUTICALS; TOMOGRAPHY, X-RAY COMPUTED;

EID: 78650598314     PISSN: 00338419     EISSN: 15271315     Source Type: Journal    
DOI: 10.1148/radiol.10092440     Document Type: Article

References (20)

1. Travaini LL, Trifirò G, Ravasi L, et al. Role of [18F]FDG-PET/CT after radiofrequency ablation of liver metastases: preliminary results. Eur J Nucl Med Mol Imaging 2008;55(7):1316-1322.
2. Langenhoff BS, Oyen WJ, Jager GJ, et al. Efficacy of fluorine-18- deoxyglucose positron emission tomography in detecting tumor recurrence after local ablative therapy for liver metastases: a prospective study. J Clin Oncol 2002;50(22):4453-4458.
3. Donckier V, Van Laethem JL, Goldman S, et al. [F-18] fluorodeoxyglucose positron emission tomography as a tool for early recognition of incomplete tumor destruction after radiofrequency ablation for liver metastases. J Surg Oncol 2003;54(4):215-223.
4. Joosten J, Jager G, Oyen W, Wobbes T, Ruers T. Cryosurgery and radiofrequency ablation for unresectable colorectal liver metastases. Eur J Surg Oncol 2005;51(10):1152-1159.
5. Veit P, Antoch G, Stergar H, Bockisch A, Forsting M, Kuehl H. Detection of residual tumor after radiofrequency ablation of liver metastasis with dual-modality PET/CT: initial results. Eur Radiol 2006;56(1):80-87.
6. Denecke T, Steffen I, Hildebrandt B, et al. Assessment of local control after laser-induced thermotherapy of liver metastases from colorectal cancer: contribution of FDG-PET in patients with clinical suspicion of progressive disease. Acta Radiol 2007;58(8):821-830.
7. Suh RD, Wallace AB, Sheehan RE, Heinze SB, Goldin JG. Unresectable pulmonary malignancies: CT-guided percutaneous radiofrequency ablation-preliminary results. Radiology 2003;529(3):821-829.
8. Herrera LJ, Fernando HC, Perry Y, et al. Radiofrequency ablation of pulmonary malignant tumors in nonsurgical candidates. J Thorac Cardiovasc Surg 2003;525(4):929-937.
9. Lee JM, Jin GY, Goldberg SN, et al. Percutaneous radiofrequency ablation for inoperable non-small cell lung cancer and metastases: preliminary report. Radiology 2004;530(1):125-134.
10. de Baère T, Palussière J, Aupérin A, et al. Midterm local efficacy and survival after radiofrequency ablation of lung tumors with minimum follow-up of 1 year: prospective evaluation. Radiology 2006;540(2):587-596.
11. Simon CJ, Dupuy DE, DiPetrillo TA, et al. Pulmonary radiofrequency ablation: longterm safety and efficacy in 153 patients. Radiology 2007;543(1):268-275.
12. Lencioni R, Crocetti L, Cioni R, et al. Response to radiofrequency ablation of pulmonary tumours: a prospective, intention-totreat, multicentre clinical trial (the RAPTURE study). Lancet Oncol 2008;5(7):621-628.
13. Vogt FM, Antoch G, Veit P, et al. Morphologic and functional changes in nontumorous liver tissue after radiofrequency ablation in an in vivo model: comparison of 18F-FDG PET/CT, MRI, ultrasound, and CT. J Nucl Med 2007;58(11):1836-1844.
14. Okuma T, Matsuoka T, Okamura T, et al. 18F-FDG small-animal PET for monitoring the therapeutic effect of CT-guided radiofrequency ablation on implanted VX2 lung tumors in rabbits. J Nucl Med 2006;57(8):1351-1358.
15. Akeboshi M, Yamakado K, Nakatsuka A, et al. Percutaneous radiofrequency ablation of lung neoplasms: initial therapeutic response. J Vasc Interv Radiol 2004;55(5):463-470.
16. Hataji O, Yamakado K, Nakatsuka A, et al. Radiological and pathological correlation of lung malignant tumors treated with percutaneous radiofrequency ablation. Intern Med 2005;54(8):865-869.
17. Okuma T, Okamura T, Matsuoka T, et al. Fluorine-18-fluorodeoxyglucose positron emission tomography for assessment of patients with unresectable recurrent or metastatic lung cancers after CT-guided radiofrequency ablation: preliminary results. Ann Nucl Med 2006;50(2):115-121.
18. Higaki F, Okumura Y, Sato S, et al. Preliminary retrospective investigation of FDG-PET/CT timing in follow-up of ablated lung tumor. Ann Nucl Med 2008;52(3):157-163.
19. Rothman KJ. Estimation of confidence limits for the cumulative probability of survival in life table analysis. J Chronic Dis 1978;51(8):557-560.
20. de Geus-Oei LF, Vriens D, van Laarhoven HW, van der Graaf WT, Oyen WJ. Monitoring and predicting response to therapy with 18F-FDG PET in colorectal cancer: a systematic review. J Nucl Med 2009;50(suppl 1):43S-54S.